RHA 2, RHA 3, RHA 4
FDA premarket approval P170002/S013 · decided 2021-03-19
Approval details
- PMA number
- P170002
- Supplement
- S013
- Supplement type
- 30-Day Notice
- Supplement reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Trade name
- RHA 2, RHA 3, RHA 4
- Generic name
- Implant, dermal, for aesthetic use
- Applicant
- Teoxane S.A.
- Date received
- 2021-02-17
- Decision date
- 2021-03-19
- Days to decision
- 30 days
- Decision code
- OK30
- Product code
- LMH
- Advisory committee
- General, Plastic Surgery
- Expedited review
- No
- Location
- Geneva
- Statement
- Declare the change of analytical laboratory in charge of the assay of sodium hyaluronate (NaHA) content in the finished products at the release step for RHA2, RHA3, and RHA4.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.